Mepolizumab in eosinophilic disorders (Q35446671)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

review article

2 references

28 September 2020

Mepolizumab in eosinophilic disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

0 references

1 reference

28 September 2020

Churg-Strauss syndrome

1 reference

hypereosinophilic syndrome

28 September 2020

1 reference

28 September 2020

1 reference

27 September 2019

1 reference

22 August 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Philip E Putnam

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 July 2011

14 references

12 March 2019

13 March 2019

3 April 2019

17 June 2019

30 June 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

25 July 2020

22 August 2020

28 September 2020

Expert Review of Clinical Immunology

14 references

12 March 2019

13 March 2019

3 April 2019

17 June 2019

30 June 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

25 July 2020

22 August 2020

28 September 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

411-417

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody

8 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Clinical manifestations and treatment of Churg-Strauss syndrome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Involvement of mast cells in eosinophilic esophagitis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Mepolizumab and exacerbations of refractory eosinophilic asthma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

The hypereosinophilic syndromes: current concepts and treatments

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Approach to the therapy of hypereosinophilic syndromes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Eosinophilic esophagitis disease in children from West Virginia: a review of the last decade (1995-2004).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

12 July 2018

Eosinophilic esophagitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Clinical and Endoscopic Features of Eosinophilic Esophagitis in Adults

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Esophageal eosinophilia in children with dysphagia

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Eosinophilic esophagitis: it's not just kid's stuff

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

An etiological role for aeroallergens and eosinophils in experimental esophagitis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Recombinant human interleukin 5 is a selective activator of human eosinophil function

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Interleukin-5, eosinophils, and disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Eosinophilic esophagitis in 29 pediatric patients

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Incidence of inflammatory bowel disease in Finnish children, 1987-2003.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

A critical role for eosinophils in allergic airways remodeling.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Defining a link with asthma in mice congenitally deficient in eosinophils.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in wisconsin: a statewide population-based study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Treatment of hypereosinophilic syndrome with imatinib mesilate

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201786

The Three-Dimensional Structure of Human Interleukin-5 at 2.4-Angstroms Resolution: Implication for the Structures of Other Cytokines

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1586%2FECI.11.27

Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1586%2FECI.11.27

Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1586%2FECI.11.27

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys

21 January 2018

1 reference

12 December 2020

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome

1 reference

12 December 2020

Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years

1 reference

12 December 2020

Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Structure of recombinant human interleukin 5 produced by Chinese hamster ovary cells

1 reference

12 December 2020

Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge

1 reference

12 December 2020

Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation

1 reference

12 December 2020

Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness

1 reference

12 December 2020

Eosinophilic esophagitis: Escalating epidemiology?

1 reference

12 December 2020

Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis

1 reference

12 December 2020

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial

1 reference

12 December 2020

Sustained response to mepolizumab in refractory Churg-Strauss syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1586/ECI.11.27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790283%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference